Sorrento to Present New Data on Advanced Immunotherapies at ASH 2019 and Other Conferences

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) reearch team will participate in upcoming industry conferences in the 4th quarter 2019. Sorrento will provide new data on recent advances in allogeneic cellular therapy research, including but not limited to 3 clinica

Benzinga · 11/07/2019 08:27

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) reearch team will participate in upcoming industry conferences in the 4th quarter 2019.

Sorrento will provide new data on recent advances in allogeneic cellular therapy research, including but not limited to 3 clinical areas Sorrento has been focusing on:

original Dimeric Antigen Receptor DAR (proprietary) approach
non-viral gene editing knock-out knock-in KOKI (proprietary) technology
allogeneic manufacturing aiming at increasing capacity and reducing end-patient-costs
Examples from the CD38 and BCMA programs will illustrate current progress in key development areas.

Several scientific posters will be presented at the upcoming Society of Immunotherapy of Cancer and American Society of Hematology conferences and will be available following the event.

Zhangjiang International Summit on Cell Therapy 2019

Date: November 14th

Time: 11:15 AM China Time

Location: Shanghai

Next-generation off-the-shelf CAR-T cell therapy

Keynote Speaker, Dr. Henry Ji

American Society of Hematology (ASH Scientific Conference)

Date: December 7th through 10th

Location: Orange County Convention Center (OCCC), Orlando, Fl

Development of an Allogeneic Anti-BCMA T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure. Poster and audio.

Development of a Genetically Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure. Poster and audio.

Preclinical characterization of an anti-CD38/CD3 T Cell- redirecting bispecific antibody. Poster and audio.

Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies. (Sorrento sourced technology presented by Celularity).

Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) as Allogeneic Cancer Immunotherapy. (Sorrento sourced technology presented by Celularity).

Ex-vivo activity of immuno-therapeutic approaches targeting CD38 against Daratumumab-resistant multiple myeloma patient samples. (Collaborative work between Sorrento and Karolinska institute). Late breaking abstract submission.
ASH online (following scientific conference)

Preclinical Development of a BCMA Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy. Selected for inclusion in November supplemental issue of Blood and for ASH online abstracts.

Preclinical Development of a CD38 Targeting Antibody-Drug Conjugate for Treatment of Hematological Malignancies. Selected for inclusion in November supplemental issue of Blood and for ASH online abstracts.
Longwood Annual Winter Meeting at Harvard Medical School 2019

Date: December 10th

Time: 8:30 AM Eastern Time

Location: Harvard Medical School, Joseph B. Martin Conference Center, Boston, MA

Identifying Novel Technologies and Therapeutic Areas

Expert panel discussion with Dr. Henry Ji